- Home
- NRO vs STTK Comparison
NRO vs STTK Comparison
Compare NRO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- STTK
- Stock Information
- Founded
- NRO 2003
- STTK 2016
- Country
- NRO United States
- STTK United States
- Employees
- NRO N/A
- STTK N/A
- Industry
- NRO Finance/Investors Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- STTK Health Care
- Exchange
- NRO Nasdaq
- STTK Nasdaq
- Market Cap
- NRO 156.7M
- STTK 83.8M
- IPO Year
- NRO N/A
- STTK 2020
- Fundamental
- Price
- NRO $3.26
- STTK $1.94
- Analyst Decision
- NRO
- STTK Hold
- Analyst Count
- NRO 0
- STTK 6
- Target Price
- NRO N/A
- STTK $2.67
- AVG Volume (30 Days)
- NRO 239.4K
- STTK 1.6M
- Earning Date
- NRO 01-01-0001
- STTK 11-13-2025
- Dividend Yield
- NRO 11.41%
- STTK N/A
- EPS Growth
- NRO N/A
- STTK N/A
- EPS
- NRO N/A
- STTK N/A
- Revenue
- NRO N/A
- STTK $2,997,000.00
- Revenue This Year
- NRO N/A
- STTK N/A
- Revenue Next Year
- NRO N/A
- STTK N/A
- P/E Ratio
- NRO N/A
- STTK N/A
- Revenue Growth
- NRO N/A
- STTK N/A
- 52 Week Low
- NRO $2.51
- STTK $0.69
- 52 Week High
- NRO $3.45
- STTK $3.95
- Technical
- Relative Strength Index (RSI)
- NRO 49.50
- STTK 64.83
- Support Level
- NRO $3.23
- STTK $1.68
- Resistance Level
- NRO $3.37
- STTK $2.01
- Average True Range (ATR)
- NRO 0.05
- STTK 0.23
- MACD
- NRO -0.00
- STTK 0.05
- Stochastic Oscillator
- NRO 32.35
- STTK 80.82
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.